Drug details

Ingrezza (valbenazine capsules)

type of VMAT2 Inhibitors

Ingrezza (valbenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• fluttering in your chest,
• shortness of breath, and
• pounding heartbeats,
• lightheadedness
• extreme drowsiness,
• fast, slow, or uneven heartbeats,

The following drugs are related to Ingrezza, either as a replacement or used together:

• Abilify (aripiprazole)
• Abilify Maintena (aripiprazole extended-release injectable suspension)
• Rexulti (brexpiprazole tablets)
• Buspar (buspirone)
• Fanapt (iloperidone tablets)
• Prolixin (fluphenazine)
• Haldol (haloperidol injection)
• Invega (paliperidone)
• Loxitane (loxapine)
• Reglan (metoclopramide)
• Reglan Injection (metoclopramide injection)
• Reglan ODT (metoclopramide orally disintegrating tablets)
• Moban (molindone hydrochloride tablets)
• Zyprexa (olanzapine)